FDA label
What is Aubagio used for?
Aubagio contains teriflunomide. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “AUBAGIO® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Aubagio?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Aubagio, tablet, film coated
Indications and Usage, quoted from the label by Genzyme Corporation (NDA202992). Cross-references to other label sections are left out.
AUBAGIO® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Source: DailyMed label, set id 4650d12c-b9c8-4525-b07f-a2d773eca155, version 28, effective February 20, 2026. NDC 58468-0210, one of 2 listings for this product.
Questions
What is Aubagio used for?
The FDA label says: “AUBAGIO® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”
What drug class is Aubagio?
FDA lists teriflunomide in the Pyrimidine Synthesis Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.